BackFresh Tracks Therapeutics Overview

Fresh Tracks Therapeutics EBIT

Latest ebit for FRTX: $-5.9M, below the Healthcare sector average of $1.9T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$1.24M
↑ 73.05% YoY

As of Dec 31, 2023

Annual EBIT (TTM)

-$5.88M
↑ 72.72% YoY

Trailing 12 months ending Dec 31, 2023

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Fresh Tracks Therapeutics (FRTX) FAQ

Fresh Tracks Therapeutics (FRTX) currently reports a EBIT of $-5.9M as of December 2023. That compares with $-22M in the prior-year period — up 72.7% year over year. That is below the Healthcare sector average of $1.9T. Use the charts on this page to explore Fresh Tracks Therapeutics's EBIT history and peer comparisons.

Fresh Tracks Therapeutics's EBIT increased from $-22M to $-5.9M — a 72.7% year-over-year increase (period ending December 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Fresh Tracks Therapeutics's EBIT of $-5.9M is lower than the Healthcare sector average of $1.9T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Fresh Tracks Therapeutics reported $-5.9M in EBIT as of December 2023. That compares with $-22M in the prior-year period — up 72.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-5.9M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $1.9T. From there, open related valuation or income-statement pages for Fresh Tracks Therapeutics, and consider following FRTX for alerts when major investors trade the stock.